NetworkNewsBreaks – Lexaria Bioscience Corp. (NA
Post# of 420
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its continued accumulation of international patent recognition with the receipt of its first granted patent in Canada, which is its 28th granted patent worldwide. According to the update, Canadian Patent #3,093,414 is the first granted patent from Lexaria’s sixth patent family and is entitled “Transdermal and/or Dermal Delivery of Lipophilic Active Agents.” The patent covers improved compositions and methods for dermal and transdermal delivery of cannabinoids, including cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”). Similar patent applications for skin-based delivery of DehydraTECH(TM) formulations are pending in many other countries.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer